Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases

Oncotarget

Volumn 7, Issue 11, 2016, Pages 12612-12622

  Wang, Zhiyu ^a   Wen, Xiaoting ^a   Lu, Yaohong ^a   Yao, Yang ^a   Zhao, Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Bone metastases; Decision tree; Machine learning; Skeletal related events; Support vector machine

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTERMINAL PROPEPTIDE OF TYPE 1 COLLAGEN; BONE SPECIFIC ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DISEASE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DATA ANALYSIS; DECISION TREE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME ASSAY; FEMALE; FRANKEL GRADE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIREL SCORE; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SKELETAL RELATED EVENT; SUPPORT VECTOR MACHINE; VISUAL ANALOG SCALE; AGED; BONE TUMOR; COMPLICATION; SECONDARY; STATISTICAL MODEL;

ADULT; AGED; BONE DISEASES; BONE NEOPLASMS; DECISION TREES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; SUPPORT VECTOR MACHINE;

EID: 84962920890     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7278     Document Type: Article

References (32)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12:6243s-6249s.
2. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 7:165-176.
3. Cook RJ, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst. 2001; 93:534-538.
4. Kosteva J, Langer C. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol. 2008; 20:155-161.
5. Coleman RE. Skeletal complications of malignancy. Cancer. 1997; 80:1588-1594.
6. Coleman RE. Bisphosphonates: Clinical experience. Oncologist. 2004; 9 suppl 4:14-27.
7. Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist. 2004; 9: 687-695.
8. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000; 88:1082-1090.
9. Saad F, McKiernan J, Eastham J. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. Urol Oncol. 2006; 24: 4-12.
10. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100: 2613-2621.
11. Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184:162-167.
12. Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat. 2011; 129:495-503.
13. Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA. Health-related quality of life among patients with breast cancer receiving Zometa or pamidronate disodium for metastatic bone lesions. Med Care. 2004; 42:164-175.
14. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA. The significance of skeletal-related events for the healthrelated quality of life of patients with metastatic prostate cancer. Ann Oncol. 2005; 16:579-584.
15. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer. 2008; 16:879-889.
16. Lee SK, Son YJ, Kim J, Kim HG, Lee JI, Kang BY, Cho HS, Lee S. Prediction model for Health-Related Quality of life of elderly with chronic diseases using Machine LearningTechniques. Healthc Inform Res. 2014; 2:125-134.
17. Hosseinzadeh F, Kayvanjoo AH, Ebrahimi M, Goliaei B. Prediction of lung tumor types based on protein attributes by machine learning algorithms. Springer Plus. 2013; 2: 1-14.
18. Dreiseitl S, Ohno-Machado L. Logistic regression and artificial neural network classification models: a methodology review. J Biomed Inform. 2002; 35:352-359.
19. Salama GI, Abdelhalim M, Zeid MA-e. Breast Cancer Diagnosis on Three Different Datasets using Multi-classifiers. International Journal of Computer and Information Technology. 2012; 1:36-43.
20. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988; 16:195-202.
21. Frankel HL, Hancock DO, Hyslop G, Melzak J, Michaelis LS, Ungar GH, Vernon JD, Walsh JJ. The value of posturalreduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia. Paraplegia. 1969; 7:179-192.
22. Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathological fractures. Clin Orthop. 1989; 249:256-264.
23. Zekic-Susac M, Pfeifer S, Durdevic I. Classification of entrepreneurial INTENTIONS by neural networks, decision trees and support vector machines. Croatian Operational Research Review. 2010; 1:62-71.
24. Lee SK, Kang BY, Kim HG, Son YJ. Predictors of medication adherence in elderly patients with chronic diseases using support vector machinemodels. Healthc Inform Res. 2013; 1:33-41.
25. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988; 240:1285-1293.
26. Son MS, Moon PS. Big data era of Korea, if you do not want to Galapagos. Seoul: LG Business Insight. 2012 Available from: http://www.lgeri.com/uploadFiles/ko/pdf/ind/LGBI1188-02_20120313130223.pdf Accessed Mar 2014.
27. Lim SJ, Min OK. Machine learning technology trends for big data processing. Electron Telecommun Trends. 2012; 27:55-63.
28. Duda, RO, Hart, PE, Stork, DG. Pattern Classification. 2. John Wiley and Sons. 2000.
29. Breiman L. Statistical Modeling: The Two Cultures. Statistical Science. 2001; 16:199-231.
30. Cook EF, Goldman L. A symmetric stratification. An outline for an efficient method for controlling confounding in cohort studies. Am J Epidemiol. 1988; 127:626-639.
31. Wang Z, Zhen Y, Wu C, Li H, Yang Y, Shen Z, Zhao H, Yao Y. CT fluoroscopy-guided percutaneous osteoplasty for the treatment of osteolytic lung cancer bone metastases to the spine and pelvis. J Vasc Interv Radiol. 2012; 23:1135-1142.
32. Wang Z, Qiao D, Lu Y, Curtis D, Wen X, Yao Y, Zhao H. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. Oncologist. 2015; 20:440-449.